Please note: The information displayed on this page might be outdated.
IO Biotech: IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
Company Participants at Danish Science and The City DKBIO 17
- Kapil Dhingra, MD, PhD, Strategic Advisor
- Mai-Britt Zocca, PhD, Co-Founder & CEO